Cowen Starts Versartis (VSAR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- S&P Global explores potential separation of Capital IQ business
- SpaceX stock drops amid spaceport lawsuit, debt concerns
Citi Starts Versartis (VSAR) at Buy
April 15, 2014 7:05 AM EDTCiti initiated coverage on Versartis (NASDAQ: VSAR) with a Buy rating and a price target of $60.00.
For an analyst ratings summary and ratings history on Versartis click here. For more ratings news on Versartis click here.
Shares of Versartis closed at $24.56 yesterday.
... MoreMorgan Stanley Starts Versartis (VSAR) at Overweight
April 15, 2014 7:04 AM EDTMorgan Stanley initiated coverage on Versartis (NASDAQ: VSAR) with an Overweight rating and a price target of $79.00.
For an analyst ratings summary and ratings history on Versartis click here. For more ratings news on Versartis click here.
Shares of Versartis closed at $24.56 yesterday.
... MoreUPDATE: Canaccord Genuity Starts Versartis (VSAR) at Buy
April 15, 2014 7:03 AM EDT(Updated - April 15, 2014 11:38 AM EDT)
Canaccord Genuity initiated coverage on Versartis (NASDAQ: VSAR) with a Buy rating and a price target of $36.00.
"We believe Versartis product treating growth hormone deficiency is differentiated molecularly and provides significant advantages over current treatment including... More



